keyword
MENU ▼
Read by QxMD icon Read
search

Phase 3 hematology

keyword
https://www.readbyqxmd.com/read/28936148/the-potential-anticoagulant-property-of-caulerpa-lentillifera-crude-extract
#1
Althea R Arenajo, Adrian P Ybañez, Maria Maichol P Ababan, Charlotte E Villajuan, May Rose M Lasam, Chiqui P Young, Julie Lynn A Reyes
BACKGROUND: Anticoagulants have been used in the treatment of several circulatory diseases and thrombotic disorders, and in the blood sampling for hematologic analysis. Sulfated polysaccharides (SP), which have anticoagulant properties, are found in most seaweeds, including Caulerpa spp. OBJECTIVE: The study generally aimed to evaluate the potential anticoagulant property of Caulerpa lentillifera. METHODOLOGY: The whole plant of fresh C. lentillifera was washed thoroughly with distilled water and manually expressed to obtain the extract...
July 2017: International Journal of Health Sciences
https://www.readbyqxmd.com/read/28935542/phase-i-trial-of-veliparib-a-poly-adp-ribose-polymerase-inhibitor-plus-metronomic-cyclophosphamide-in-metastatic-her2-negative-breast-cancer
#2
Jesus Anampa, Alice Chen, John Wright, Margi Patel, Christine Pellegrino, Karen Fehn, Joseph A Sparano, Eleni Andreopoulou
BACKGROUND: Poly-ADP-ribose-polymerase is an essential nuclear enzyme, involved in base-excision repair of damaged DNA. Poly-ADP-ribose-polymerase inhibition sensitizes tumor cells to cytotoxic agents, which induce DNA damage, including cyclophosphamide (C), and metronomic dosing of C may optimize potential for synergy. METHODS: The primary objective of this phase I trial was to determine the safety and identify the recommended phase II dose of the combination of low-dose oral C (50, 75, 100, and 125 mg) once daily in combination with veliparib (V) (100, 200, and 300 mg) administered twice a day (BID) for 21-day cycles using a standard 3 + 3 design in patients with metastatic human epidermal growth factor receptor 2/neu-negative breast cancer...
September 1, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28930494/simplify-1-a-phase-iii-randomized-trial-of-momelotinib-versus-ruxolitinib-in-janus-kinase-inhibitor-na%C3%A3-ve-patients-with-myelofibrosis
#3
Ruben A Mesa, Jean-Jacques Kiladjian, John V Catalano, Timothy Devos, Miklos Egyed, Andrzei Hellmann, Donal McLornan, Kazuya Shimoda, Elliott F Winton, Wei Deng, Ronald L Dubowy, Julia D Maltzman, Francisco Cervantes, Jason Gotlib
Purpose We evaluated the efficacy and safety of momelotinib, a potent and selective Janus kinase 1 and 2 inhibitor (JAKi), compared with ruxolitinib, in JAKi-naïve patients with myelofibrosis. Patients and Methods Patients (N = 432) with high risk or intermediate-2 risk or symptomatic intermediate-1 risk myelofibrosis were randomly assigned to receive 24 weeks of treatment with momelotinib 200 mg once daily or ruxolitinib 20 mg twice a day (or per label), after which all patients could receive open-label momelotinib...
September 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28922466/blinatumomab-pharmacodynamics-and-exposure-response-relationships-in-relapsed-refractory-acute-lymphoblastic-leukemia
#4
Min Zhu, Andrea Kratzer, Jessica Johnson, Chris Holland, Christian Brandl, Indrajeet Singh, Andreas Wolf, Sameer Doshi
We evaluated blinatumomab pharmacokinetics, pharmacodynamics (CD3+ T-cell, CD19+ B-cell, and cytokine levels), and their associations with efficacy or safety in relapsed/refractory acute lymphoblastic leukemia. Blinatumomab pharmacokinetics (continuous intravenous infusion) from a phase 2 study (n = 189; NCT01466179) were assessed noncompartmentally. Associations between steady-state concentration (Css ) and efficacy (complete remission [CR] or CR with partial hematologic recovery [CRh]) or safety (cytokine release syndrome [CRS] and neurologic events [NEs]) were evaluated with statistical models...
September 18, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28919394/concomitant-chemotherapy-and-radiotherapy-with-sbrt-boost-for-unresectable-stage-iii-non-small-cell-lung-cancer-a-phase-i-study
#5
Kristin A Higgins, Rathi N Pillai, Zhengjia Chen, Sibo Tian, Chao Zhang, Pretesh Patel, Suchita Pakkala, Jay Shelton, Seth D Force, Felix G Fernandez, Conor E Steuer, Taofeek K Owonikoko, Suresh S Ramalingam, Jeffrey D Bradley, Walter J Curran
PURPOSE: Stereotactic Body Radiation Therapy (SBRT) is now the standard of care in medically inoperable stage I non-small cell lung cancer, yielding high rates of local control. It is unknown if SBRT can be safely utilized in the locally advanced NSCLC setting. This multi-institution phase I study evaluated the safety of 44 Gy conventionally fractionated thoracic radiation with concurrent chemotherapy plus a dose escalated SBRT boost to both the primary tumor and involved mediastinal lymph nodes...
September 12, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28911922/neoadjuvant-sorafenib-gemcitabine-and-cisplatin-administration-preceding-cystectomy-in-patients-with-muscle-invasive-urothelial-bladder-carcinoma-an-open-label-single-arm-single-center-phase-2-study
#6
Andrea Necchi, Salvatore Lo Vullo, Daniele Raggi, Federica Perrone, Patrizia Giannatempo, Giuseppina Calareso, Elena Togliardi, Nicola Nicolai, Luigi Piva, Davide Biasoni, Mario Catanzaro, Tullio Torelli, Silvia Stagni, Maurizio Colecchia, Adele Busico, Marzia Pennati, Nadia Zaffaroni, Luigi Mariani, Roberto Salvioni
BACKGROUND: Outcomes of neoadjuvant chemotherapy in patients with muscle-invasive urothelial bladder carcinoma (MIUBC) should be improved. Sorafenib was combined with gemcitabine and cisplatin chemotherapy (SGC) in an open-label, single-arm, phase 2 trial (NCT01222676). PATIENTS AND METHODS: After transurethral resection of the bladder, T2-T4a N0 patients received four cycles of SGC followed by cystectomy. Sorafenib 400mg q12h daily, continuously, was added to standard GC chemotherapy...
September 11, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28911085/a-randomized-open-label-multicenter-phase-3-study-to-compare-the-efficacy-and-safety-of-eribulin-to-treatment-of-physician-s-choice-in-patients-with-advanced-non-small-cell-lung-cancer
#7
N Katakami, E Felip, D R Spigel, J-H Kim, M Olivo, M Guo, H Nokihara, J C-H Yang, N Iannotti, M Satouchi, F Barlesi
Background: Eribulin is a microtubule dynamics inhibitor with a novel mechanism of action. This phase 3 study aimed to compare overall survival (OS) in patients with heavily pretreated non-small cell lung cancer (NSCLC) receiving eribulin to treatment of physician's choice (TPC). Patients and methods: Patients with advanced NSCLC who had received ≥2 prior therapies, including platinum-based doublet and epidermal growth factor receptor tyrosine kinase inhibitor, were randomly assigned to receive eribulin or TPC (gemcitabine, pemetrexed, vinorelbine, docetaxel)...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28910150/phase-i-ii-trial-of-anticarcinoembryonic-antigen-radioimmunotherapy-gemcitabine-and-hepatic-arterial-infusion-of-fluorodeoxyuridine-postresection-of-liver-metastasis-for-colorectal-carcinoma
#8
Benjamin Cahan, Lucille Leong, Lawrence Wagman, David Yamauchi, Stephen Shibata, Sharon Wilzcynski, Lawrence E Williams, Paul Yazaki, David Colcher, Paul Frankel, Anna Wu, Andrew Raubitschek, John Shively, Jeffrey Y C Wong
OBJECTIVES: Report the feasibility, toxicities, and long-term results of a Phase I/II trial of (90)Y-labeled anticarcinoembryonic antigen (anti-CEA) (cT84.66) radioimmunotherapy (RIT), gemcitabine, and hepatic arterial infusion (HAI) of fluorodeoxyuridine (FUdR) after maximal hepatic resection of metastatic colorectal cancer to the liver. METHODS: Patients with metastatic colorectal cancer to the liver postresection or ablation to minimum disease were eligible. Each cohort received HAI of FUdR for 14 days on a dose escalation schedule...
September 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28898281/randomized-prospective-study-evaluating-tenofovir-disoproxil-fumarate-prophylaxis-against-hepatitis-b-virus-reactivation-in-anti-hbc-positive-patients-with-rituximab-based-regimens-to-treat-hematologic-malignancies-the-preblin-study
#9
María Buti, María L Manzano, Rosa M Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M Zozaya, Miguel A Simón, Luis E Morano, José L Calleja, María Yébenes, Rafael Esteban
BACKGROUND: Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is uncertain. The aim of this study was to compare the efficacy of tenofovir disoproxil fumarate (TDF) prophylaxis versus close monitoring in antiHBc-positive, HBsAg-negative patients under treatment with rituximab (RTX)-based regimens for hematologic malignancy. METHODS: PREBLIN is a phase IV, randomized, prospective, open-label, multicenter, parallel-group trial conducted in 17 hospitals throughout Spain...
2017: PloS One
https://www.readbyqxmd.com/read/28894576/first-line-chemotherapy-with-capecitabine-oxaliplatin-for-advanced-gastric-cancer-a-phase-i-study
#10
Hironaga Satake, Hisateru Yasui, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Masahito Kotaka, Takeshi Kato, Akihito Tsuji
Combination chemotherapy with capecitabine and oxaliplatin for gastric cancer (G-XELOX) is considered as a potentially promising regimen. However, the use of the G-XELOX regimen in Japanese patients has not been investigated to date, and recommended doses of G-XELOX for Japanese patients with metastatic gastric cancer have not been established. The aim of the present study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) for systemic chemotherapy with G-XELOX for metastatic gastric cancer...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28890824/gemcitabine-and-capecitabine-for-advanced-biliary-cancer
#11
Emmanuel Gabriel, Shipra Gandhi, Kristopher Attwood, Boris Kuvshinoff, Steven Hochwald, Renuka Iyer
BACKGROUND: Gemcitabine with capecitabine (gem-cap) is an established regimen for advanced biliary cancer (ABC) supported by our previously reported phase II trial. Here, we provide our updated experience. METHODS: Single institution, retrospective study from 2005 to 2015 of ABC treated with gem-cap. RESULTS: A total of 372 patients with ABC were identified, of whom 227 (61.0%) were treated with chemotherapy. 153 patients (67.4%) received gem-cap, of which 129 (56...
August 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28880867/oral-tetrahydrouridine-and-decitabine-for-non-cytotoxic-epigenetic-gene-regulation-in-sickle-cell-disease-a-randomized-phase-1-study
#12
RANDOMIZED CONTROLLED TRIAL
Robert Molokie, Donald Lavelle, Michel Gowhari, Michael Pacini, Lani Krauz, Johara Hassan, Vinzon Ibanez, Maria A Ruiz, Kwok Peng Ng, Philip Woost, Tomas Radivoyevitch, Daisy Pacelli, Sherry Fada, Matthew Rump, Matthew Hsieh, John F Tisdale, James Jacobberger, Mitch Phelps, James Douglas Engel, Santhosh Saraf, Lewis L Hsu, Victor Gordeuk, Joseph DeSimone, Yogen Saunthararajah
BACKGROUND: Sickle cell disease (SCD), a congenital hemolytic anemia that exacts terrible global morbidity and mortality, is driven by polymerization of mutated sickle hemoglobin (HbS) in red blood cells (RBCs). Fetal hemoglobin (HbF) interferes with this polymerization, but HbF is epigenetically silenced from infancy onward by DNA methyltransferase 1 (DNMT1). METHODS AND FINDINGS: To pharmacologically re-induce HbF by DNMT1 inhibition, this first-in-human clinical trial (NCT01685515) combined 2 small molecules-decitabine to deplete DNMT1 and tetrahydrouridine (THU) to inhibit cytidine deaminase (CDA), the enzyme that otherwise rapidly deaminates/inactivates decitabine, severely limiting its half-life, tissue distribution, and oral bioavailability...
September 2017: PLoS Medicine
https://www.readbyqxmd.com/read/28872489/a-case-of-pure-red-cell-aplasia-during-nivolumab-therapy-for-cardiac-metastatic-melanoma
#13
Akihiko Yuki, Tatsuya Takenouchi, Sumiko Takatsuka, Takuro Ishiguro
Nivolumab is an antibody against programmed cell death 1 and functions as an immune checkpoint inhibitor for various malignancies, including unresectable melanomas. Nivolumab causes several immune-related adverse events, which typically include skin rash, pneumonitis, thyroid dysfunction, hepatitis, and colitis; in rare cases, anemia may be present. There are several reports of autoimmune hemolytic anemia that has developed in response to nivolumab; however, there are few reports of pure red cell aplasia (PRCA)...
September 1, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28871553/treatment-with-granulocyte-colony-stimulating-factor-in-the-refeeding-phase-of-anorexia-nervosa-complicated-with-severe-neutropenia-and-sepsis-a-case-report
#14
Haruki Komatsu, Karin Hayashi, Fukiko Higashiyama
Leukopenia is frequently observed in patients with anorexia nervosa (AN). However, serious infectious diseases are infrequent in patients with AN. We present the case of a 13-year-old girl with AN complicated with severe neutropenia and sepsis upon refeeding. Her body mass index was 11 kg/m(2) and her absolute neutrophil count (ANC) was 1555/µL on admission. After the initiation of refeeding, her ANC gradually declined to 346/µL. High fever occurred and a blood culture tested positive for Enterobacter cloacae...
September 4, 2017: Eating and Weight Disorders: EWD
https://www.readbyqxmd.com/read/28870789/panitumumab-in-combination-with-preoperative-radiation-therapy-in-patients-with-locally-advanced-ras-wild-type-rectal-cancer-results-of-the-multicenter-explorative-single-arm-phase-2-study-neorit
#15
Kirsten Merx, Uwe M Martens, Melanie Kripp, Thomas Hoehler, Michael Geissler, Timo Gaiser, Sabine Mai, Peter Kienle, Sebastian Belle, Christoph Plöger, Udo Hieber, Frederik Wenz, Stefan Post, Ralf D Hofheinz
PURPOSE: Studies investigating combinations of anti-epidermal growth factor receptor monoclonal antibodies such as panitumumab or cetuximab with standard chemoradiation therapy protocols in rectal cancer have yielded disappointing results. Because of the supposed negative interaction of epidermal growth factor receptor inhibition and chemoradiation therapy, we conducted a phase 2 study using single-agent panitumumab in combination with radiation therapy in patients with RAS wild-type locally advanced rectal cancer...
June 28, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28860655/pomalidomide-dexamethasone-in-refractory-multiple-myeloma-long-term-follow-up-of-a-multi-cohort-phase-ii-clinical-trial
#16
S Ailawadhi, J R Mikhael, B R LaPlant, K M Laumann, S Kumar, V Roy, D Dingli, P L Bergsagel, F K Buadi, S V Rajkumar, R Fonseca, M A Gertz, P Kapoor, T Sher, S R Hayman, A K Stewart, A Dispenzieri, R A Kyle, W I Gonsalves, C B Reeder, Y Lin, R S Go, N Leung, T Kourelis, J A Lust, S J Russell, A A Chanan-Khan, M Q Lacy
Despite therapeutic advances, multiple myeloma remains incurable, with limited options for patients with refractory disease. We conducted a large, multi-cohort clinical trial testing various doses and treatment schedules of pomalidomide and dexamethasone (Pom/dex) in patients with refractory multiple myeloma. Overall 345 patients were enrolled to six cohorts based on number and type of prior lines of therapy, pomalidomide dose and schedule. Median prior lines of therapy were 3 with near universal prior exposure to proteasome inhibitors and/or immunomodulatory drugs...
September 1, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28860342/cudc-907-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-including-patients-with-myc-alterations-results-from-an-expanded-phase-1-trial
#17
Yasuhiro Oki, Kevin R Kelly, Ian Flinn, Manish R Patel, Robert Gharavi, Anna Ma, Jefferson Parker, Amir Hafeez, David Tuck, Anas Younes
CUDC-907 is a first-in-class, oral small molecule inhibitor of both HDAC (class I and II) and PI3K (class Iα, β, and δ) enzymes, with demonstrated anti-tumor activity in multiple preclinical models, including MYC-driven ones. In this report the safety and preliminary activity results of CUDC-907, with and without rituximab, in patients with relapsed/refractory diffuse large B-cell lymphoma are presented, with a particular focus on those with MYC-altered disease. Thirty-seven diffuse large B-cell lymphoma patients were enrolled, 14 with confirmed MYC-altered disease...
August 31, 2017: Haematologica
https://www.readbyqxmd.com/read/28843693/leukocyte-profile-gene-expression-acute-phase-response-and-metabolite-status-of-cows-with-sole-hemorrhages
#18
Keelin O'Driscoll, Matthew McCabe, Bernadette Earley
Sole hemorrhages result from disruption to normal claw horn formation and are caused by a variety of internal and external factors. Evidence suggests that they are painful, although they do not usually cause clinical lameness and are difficult to detect by observing cow gait. Little is known about how or whether sole hemorrhages affect the cow systemically. This study compared hematology profile, leukocyte gene expression, and physiological responses of cows with no/mild hemorrhages (category 1; n = 17), moderate hemorrhages (category 2; n = 18), and severe hemorrhages (category 3; n = 12)...
August 23, 2017: Journal of Dairy Science
https://www.readbyqxmd.com/read/28841236/phase-1-dose-escalation-multicenter-trial-of-pracinostat-alone-and-in-combination-with-azacitidine-in-patients-with-advanced-hematologic-malignancies
#19
Yasmin M Abaza, Tapan M Kadia, Elias J Jabbour, Marina Y Konopleva, Gautam Borthakur, Alessandra Ferrajoli, Zeev Estrov, William G Wierda, Ana Alfonso, Toh Han Chong, Charles Chuah, Liang-Piu Koh, Boon-Cher Goh, Julie E Chang, Daniel E Durkes, Maria Cielo Foudray, Hagop M Kantarjian, Xiao Qin Dong, Guillermo Garcia-Manero
BACKGROUND: Pracinostat is a potent histone deacetylase inhibitor with antitumor activity in both solid tumor and acute myeloid leukemia (AML) cell lines. Pracinostat is reported to have modest clinical activity in patients with advanced solid tumors. Given the higher preclinical sensitivity of hematologic malignancies to pracinostat, the authors conducted a phase 1 study to assess the safety, maximum tolerated dose, recommended phase 2 dose, efficacy, pharmacokinetics, and pharmacodynamics of pracinostat in patients with advanced hematological malignancies...
August 25, 2017: Cancer
https://www.readbyqxmd.com/read/28839440/phase-i-clinical-study-of-personalized-peptide-vaccination-combined-with-radiotherapy-for-advanced-hepatocellular-carcinoma
#20
Jie Shen, Li-Feng Wang, Zheng-Yun Zou, Wei-Wei Kong, Jing Yan, Fan-Yan Meng, Fang-Jun Chen, Juan Du, Jie Shao, Qiu-Ping Xu, Hao-Zhen Ren, Ru-Tian Li, Jia Wei, Xiao-Ping Qian, Bao-Rui Liu
AIM: To assess the efficacy and safety of a new treatment modality, cellular immune therapy based on personalized peptide vaccination (PPV-DC-CTL) combined with radiotherapy, for treating advanced hepatocellular carcinoma (HCC). METHODS: A total of nine patients with advanced HCC were enrolled. Multidisciplinary consultation confirmed that all the patients definitely had no opportunity of surgery, because four patients had multiple liver metastases (the number of liver lesions > 3), one patient had liver metastases and portal vein tumor thrombosis, one patient had lung and bone metastases, two patients had liver and lung metastases and one patient had liver metastasis and peritoneal metastasis...
August 7, 2017: World Journal of Gastroenterology: WJG
keyword
keyword
76866
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"